Mo1791 MyD88 Has a Key Role for OLFM4, a Novel Anti-Inflammatory Mediator in H. pylori Infection

Yan, Ming; Liu, Wenli; Joo, Jung-Soo; Sun, Jiafang; Datta, Subhradeep; Yang, Amy; Rodgers, Griffin P.; Coleman, William G.

doi:10.1016/s0016-5085(12)62645-6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experiments in a MyD88 and OLFM4 double-knockout mouse model have demonstrated that the H. pylori colonization level in the model is similar to that in wild-type mice[ 25 ]. Even though the immune and inflammatory responses are enhanced compared with those in wild-type mice, infiltration of inflammatory cells in the gastric mucosa of double-knockout mice is lower than that in OLFM4 knockout mice[ 25 ]. Additionally, knocking out OLFM4 significantly up-regulates the MyD88 expression.…”

Section: Olfm4 In H Pylori Infectionmentioning

confidence: 99%

“…Additionally, knocking out OLFM4 significantly up-regulates the MyD88 expression. It has been shown that deletion of OLFM4 indirectly increases the MyD88 expression by enhancing NOD2 expression, whereas the deficiency of MyD88 leads to a loss of the feedback inhibition of the NF-κB pathway and of the resulting response[ 25 , 26 ].…”

Section: Olfm4 In H Pylori Infectionmentioning

confidence: 99%

See 1 more Smart Citation

Olfactomedin-4 in digestive diseases: A mini-review

Wang

Chen

Zhang

et al. 2018

WJG

View full text Add to dashboard Cite

Olfactomedin-4 (OLFM4, GW112, hGC-1) is a glycoprotein belonging to the olfactomedin family. The expression of OLFM4 is strong in the small intestine, colon and prostate, and moderate in the stomach and bone marrow. Previous studies have revealed that OLFM4 is closely associated with many digestive diseases. Up-regulation of OLFM4 has been detected in the Helicobacter pylori (H. pylori)-infected gastric mucosa, inflammatory bowel disease tissue and gastrointestinal malignancies, including gastric cancer, colorectal cancer, pancreatic cancer and gallbladder cancer. Down-regulation of OLFM4 has also been detected in some cases, such as in poorly differentiated, advanced-stage and metastatic tumors. Studies using OLFM4-deficient mouse models have revealed that OLFM4 acts as a negative regulator of H. pylori-specific immune responses and plays an important role in mucosal defense in inflammatory bowel disease. Patients with OLFM4-positive gastric cancer or colorectal cancer have a better survival rate than OLFM4-negative patients. However, the prognosis is worse in pancreatic cancer patients with high levels of expression of OLFM4. The NF-κB, Notch and Wnt signaling pathways are involved in the regulation of OLFM4 expression in digestive diseases, and its role in pathogenesis is associated with anti-inflammation, apoptosis, cell adhesion and proliferation. OLFM4 may serve as a potential specific diagnostic marker and a therapeutic target in digestive diseases. Further studies are required to explore the clinical value of OLFM4.

show abstract

Section: Olfm4 In H Pylori Infectionmentioning

confidence: 99%

Section: Olfm4 In H Pylori Infectionmentioning

confidence: 99%